Hydromorphone

CHEMBL398707 Phase 4 Disetujui Small molecule
Half-Life
2-3 hours
Bioavailability
Protein Binding
Molecular Weight
285.3 g/mol
LogP
1.8
Phase
4

A potent opioid analgesic used to treat moderate to severe pain, including cancer pain and postoperative pain, by binding to opioid receptors in the central nervous system to reduce pain perception. It is several times more potent than morphine and is available in oral, intravenous, and subcutaneous formulations. Careful dose titration and monitoring for respiratory depression are essential during use.

Berat Molekul

285,3380 g/mol

LogP

1,80

TPSA

49,80 Ų

Lipinski RO5

Lulus

Area Terapeutik

Kelas Obat

Mekanisme Kerja

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

Pharmacokinetics (PK)

Half-Life 2-3 hours

Pharmacodynamics (PD)

Mekanisme

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5

InChI

InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1

Molecular Formula

C17H19NO3

HBD / HBA

1 / 4

Ikatan yang Dapat Dirotasi

0

Atom Berat

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A potent opioid analgesic used to treat moderate to severe pain, including cancer pain and postoperative pain, by binding to opioid receptors in the central nervous system to reduce pain perception. It is several times more potent than morphine and is available in oral, intravenous, and subcutaneous formulations. Careful dose titration and monitoring for respiratory depression are essential during use.

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

Key pharmacokinetic parameters for Hydromorphone: Half-life: 2-3 hours.

Yes, Hydromorphone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL398707. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5284570. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.